The goal of the conference is to bring together leading international experts in β-amyloid metabolism, vascular biology, neuropathology, stroke genetics, brain imaging, and the clinical manifestations of cerebrovascular disease to present and discuss cutting-edge data in this rapidly developing field.

A special focus will be moving the field towards clinical trials of candidate disease-modifying treatments, in particular by establishing consensus on preclinical animal data and human biomarkers for CAA trials. Other topics of discussion will be early detection methods for presymptomatic CAA and the biological and clinical interactions between CAA and Alzheimer’s disease.

The atmosphere for discussion is anticipated to be informal and lively, with ample opportunities for forming new collaborations and relationships within the growing CAA scientific and clinical communities.
CEREBRAL AMYLOID ANGIOPATHY AND RELATED MICROANGIOPATHIES

CONFERENCE DIRECTORS
Mark A. van Buchem, MD, PhD
Professor and Chief of Neuroradiology
Department of Radiology
Leiden University Medical Center
Leiden, The Netherlands

Steven M. Greenberg, MD, PhD
Professor of Neurology
Harvard Medical School
Director, Hemorrhagic Stroke Research
Massachusetts General Hospital
Stroke Research Center
Boston, Massachusetts, USA

ORGANIZING COMMITTEE
Brian J. Bacska, PhD, Boston, USA
Charlotte Cordonnier, MD, Lille, France
Wiesje van der Flier, PhD, Amsterdam, the Netherlands
Joost Haan, MD, PhD, Leiden, the Netherlands
Mathias Jucker, PhD, Tübingen, Germany
Jin-Moo Lee, MD, PhD, St. Louis, USA
Joan Montaner, MD, PhD, Barcelona, Spain
William van Nostrand, PhD, Stony Brook, New York, USA
Eric Smith, MD, Calgary, Canada
Harry V. Vinters, MD, Los Angeles, USA

TARGET AUDIENCE
Neuroscience clinicians (neurologists, geriatricians, pathologists, radiologists, allied health professionals), and translational/basic researchers and biopharmaceutical investigators with an interest in amyloid, stroke, Alzheimer’s disease, and brain aging.

OBJECTIVES
At the completion of this program, participants should be better able:
• To discuss the pathogenesis of CAA and CAA-related brain injury in relation to cerebral amyloid deposition, based on information from human and animal model studies
• To consider biomarkers of β-amyloid deposition in cerebral blood vessels versus brain parenchyma, using novel neuroimaging techniques
• To discuss the relationship between familial and sporadic CAA and other hereditary conditions including familial Alzheimer disease
• To discuss the state of the art of emerging therapies for CAA
• To consider surrogate markers of disease that are instrumental in treatment trials in CAA

Abstract submission can be done to boerhaavecongress-service@lumc.nl, deadline August 31 2012. Please add ‘CAA’ in the subject line.

Venue: Leiden University Medical Center, www.lumc.nl

Registration fees: Physicians and faculty € 350,-. Allied Health Professionals and trainees € 200,-. Please note: fees increase after 31 August with € 100,-

Accreditation will be requested at the relevant professional societies.

Practical information: Boerhaave Congress Service, T: +31 71 526 8500, E: boerhaavecongress-service@lumc.nl

Scientific information: Elmi van Beelen, T: + 31 71 526 4376, E: StafsecretariaatRadiologie@Lumc.nl

This will be the third international meeting to focus on cerebral amyloid angiopathy (CAA). The first was held in Reykjavik, Iceland in August 2007, the second in Los Angeles, California in May 2010, and the third will be organized in Leiden, the Netherlands. Leiden University Medical Center has a rich history in CAA research, having been the site where the first hereditary form of CAA associated with mutation of the β-amyloid precursor protein was identified and characterized.
Wednesday, October 24

8:30 – 9:30 Registration and coffee

Opening Session
9:30 – 9:35 Welcome
Mark van Buchem
9:35 – 10:00 The story of HCHWA-D
Joost Haan

Session 1. Detecting CAA: amyloid imaging and other biomarkers
Moderator: Harry Vinters
10:00 – 11:30 Plenaries
10:00 – 10:30 : Imaging (Mark van Buchem)
10:30 – 11:00 : Biomarkers in plasma and CSF (Joan Montaner)
11:00 – 11:30 : New agents for amyloid imaging (Greg Zipfel)
11:30 – 12:30 Submitted papers and/or short invited talks

12:30 – 14:00 Lunch

Session 2. CAA and Cerebrovascular Disease: markers and mechanisms
Moderator: Raj Kalaria
14:00 – 15:30 Plenaries
14:00 – 14:20 : Epidemiology (Meike Vernooij)
14:20 – 14:40 : Imaging (David Werring)
14:40 – 15:00 : Animal models I (Brian Bacskai)
15:00 – 15:20 : Animal models II (Masafumi Ihara)

15:30 – 16:00 Break

16:00 – 17:00 Submitted papers and/or short invited talks

Thursday, October 25

Session 3. Hereditary CAA: lessons from DIAN and AD
Moderator: Wiesje van der Flier
8:30 – 10:00 Plenaries
8:30 – 9:00 : Lessons from the Dominantly Inherited Alzheimer Network (DIAN) (Randall Bateman)
9:00 – 9:30 : Lessons from Alzheimer’s Disease (Reisa Sperling)
9:30 – 10:00 : Lessons from animal models (Mathias Jucker)

10:00 – 10:30 Break

10:30 – 11:00 Questions & Answers
11:00 – 12:00 Submitted papers and/or short invited talks
12:00 – 13:30  Lunch

Session 4. Towards Treatment I: endpoints for animal studies
Moderator: Matthew Frosch*
Session to be organized around formulating proposed guidelines for animal studies aimed at identifying candidate CAA treatments for phase I-II human trials.

13:30 – 15:00  Plenaries
   13:30 – 14:00 : Hemorrhages (Jin-Moo Lee)
   14:00 – 14:30 : Amyloid and inflammation (William Van Nostrand)
   14:30 – 15:00 : Physiologic markers (Cenk Ayata)

15:00 – 15:30  Break

15:30 – 17:00  Discussion (discussion leader: Lee)

19:00  Dinner for registrants and faculty
       Faculty Club Leiden University, Rapenburg 73, Leiden

Friday, October 26

Session 5. Towards Treatment II: endpoints for human studies
Moderators: Eric Smith
Session to be organized around formulating proposed guidelines for human phase II studies aimed at identifying candidate CAA treatments for phase III clinical trials.

8:30 – 10:00  Presentation, discussion
   8:30 – 9:00 : Physiologic endpoints (Steven Greenberg)
   9:00 – 9:30 : Hemorrhagic endpoints (Charlotte Cordonnier)
   9:30 – 10:00 : Cognitive endpoints (Julie Schneider)

10:00 – 10:30  Break

10:30 – 12:00  Discussion (discussion leader: Greenberg)

12:00  Adjourn